1-hydroxyprevitamin d3 profile

1-hydroxyprevitamin D3 (1-OH-previtamin D3) is a **precursor to vitamin D3** (cholecalciferol). It's a crucial intermediate in the **synthesis of vitamin D3 in the skin** upon exposure to ultraviolet B (UVB) radiation.

Here's why it's important for research:

* **Understanding Vitamin D3 Synthesis:** Studying 1-OH-previtamin D3 helps researchers understand the intricate steps involved in vitamin D3 production within the body. This knowledge is vital for developing strategies to optimize vitamin D synthesis, especially in individuals with limited sun exposure or who have impaired vitamin D metabolism.
* **Skin Cancer Research:** 1-OH-previtamin D3's role in UV-induced vitamin D3 synthesis is critical for investigating the link between sun exposure, vitamin D production, and skin cancer risk. Understanding how 1-OH-previtamin D3 is formed and its potential implications for skin health is crucial for developing effective sun protection strategies.
* **Development of Novel Vitamin D Analogs:** Researchers are exploring the potential of 1-OH-previtamin D3 analogs as therapeutic agents for various conditions, including bone disorders, autoimmune diseases, and certain cancers.
* **Understanding Vitamin D Deficiency:** Studying the metabolism of 1-OH-previtamin D3 can help researchers identify potential causes of vitamin D deficiency and develop effective interventions to address these deficiencies.

In summary, 1-hydroxyprevitamin D3 is a critical component of the vitamin D3 synthesis pathway and its study holds significance for various research areas including vitamin D metabolism, skin cancer, and the development of new therapeutic strategies.

1-hydroxyprevitamin D3: precursor of 1 alpha-hydroxyvitamin D3; RN given refers to (1alpha,3beta,6Z)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	6450023
MeSH ID	M0097334

Synonym
9,10-secocholesta-5(10),6,8-triene-1,3-diol, (1alpha,3beta,6z)-
pre-1alpha-hydroxyvitamin d3
41461-13-6
1alpha-hydroxyprevitamin d3
(4e,6z,8z)-(1s,3r)-4-methyl-9,10-seco-4(5),6,8-cholestatrien-3-ol
LMST03020657
1-hydroxyprevitamin d3
(1s,3r)-5-[(z)-2-[(1r,3ar,7ar)-7a-methyl-1-[(2r)-6-methylheptan-2-yl]-1,2,3,3a,6,7-hexahydroinden-4-yl]ethenyl]-4-methylcyclohex-4-ene-1,3-diol

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	4 (66.67)	18.7374
1990's	2 (33.33)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	1 (16.67%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	5 (83.33%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
calcitriol dihydroxy-vitamin D3: as a major in vitro metabolite of 1alpha,25-dihydroxyvitamin D3, produced in primary cultures of neonatal human keratinocytes	3.76	2	1	D3 vitamins; hydroxycalciol; triol	antineoplastic agent; antipsoriatic; bone density conservation agent; calcium channel agonist; calcium channel modulator; hormone; human metabolite; immunomodulator; metabolite; mouse metabolite; nutraceutical
vitamin d 2 Ergocalciferols: Derivatives of ERGOSTEROL formed by ULTRAVIOLET RAYS breaking of the C9-C10 bond. They differ from CHOLECALCIFEROL in having a double bond between C22 and C23 and a methyl group at C24.. vitamin D2 : A vitamin D supplement and has been isolated from alfalfa.	3.36	1	1	hydroxy seco-steroid; seco-ergostane; vitamin D	bone density conservation agent; nutraceutical; plant metabolite; rodenticide
phosphorus Phosphorus: A non-metal element that has the atomic symbol P, atomic number 15, and atomic weight 31. It is an essential element that takes part in a broad variety of biochemical reactions.	3.77	2	1	monoatomic phosphorus; nonmetal atom; pnictogen	macronutrient

Condition	Relationship Strength	Studies	Trials
Chronic Kidney Failure [description not available]	2	1	0
CKD-MBD [description not available]	3.77	2	1
Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.	2	1	0
Chronic Kidney Disease-Mineral and Bone Disorder Decalcification of bone or abnormal bone development due to chronic KIDNEY DISEASES, in which 1,25-DIHYDROXYVITAMIN D3 synthesis by the kidneys is impaired, leading to reduced negative feedback on PARATHYROID HORMONE. The resulting SECONDARY HYPERPARATHYROIDISM eventually leads to bone disorders.	3.77	2	1
Chronic Illness [description not available]	3.76	2	1
Glomerulonephritis, Minimal Change [description not available]	1.97	1	0
Extramembranous Glomerulopathy [description not available]	1.97	1	0
DDD MPGNII [description not available]	1.97	1	0
Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).	3.76	2	1
Nephrosis, Lipoid A kidney disease with no or minimal histological glomerular changes on light microscopy and with no immune deposits. It is characterized by lipid accumulation in the epithelial cells of KIDNEY TUBULES and in the URINE. Patients usually show NEPHROTIC SYNDROME indicating the presence of PROTEINURIA with accompanying EDEMA.	1.97	1	0
Glomerulonephritis, Membranoproliferative Chronic glomerulonephritis characterized histologically by proliferation of MESANGIAL CELLS, increase in the MESANGIAL EXTRACELLULAR MATRIX, and a thickening of the glomerular capillary walls. This may appear as a primary disorder or secondary to other diseases including infections and autoimmune disease SYSTEMIC LUPUS ERYTHEMATOSUS. Various subtypes are classified by their abnormal ultrastructures and immune deposits. Hypocomplementemia is a characteristic feature of all types of MPGN.	1.97	1	0
Glomerulonephritis, Membranous A type of glomerulonephritis that is characterized by the accumulation of immune deposits (COMPLEMENT MEMBRANE ATTACK COMPLEX) on the outer aspect of the GLOMERULAR BASEMENT MEMBRANE. It progresses from subepithelial dense deposits, to basement membrane reaction and eventual thickening of the basement membrane.	1.97	1	0
Bright Disease A historical classification which is no longer used. It described acute glomerulonephritis, acute nephritic syndrome, or acute nephritis. Named for Richard Bright.	3.36	1	1
Glomerulonephritis Inflammation of the renal glomeruli (KIDNEY GLOMERULUS) that can be classified by the type of glomerular injuries including antibody deposition, complement activation, cellular proliferation, and glomerulosclerosis. These structural and functional abnormalities usually lead to HEMATURIA; PROTEINURIA; HYPERTENSION; and RENAL INSUFFICIENCY.	3.36	1	1
Age-Related Osteoporosis [description not available]	1.97	1	0
Menopause The last menstrual period. Permanent cessation of menses (MENSTRUATION) is usually defined after 6 to 12 months of AMENORRHEA in a woman over 45 years of age. In the United States, menopause generally occurs in women between 48 and 55 years of age.	1.97	1	0
Osteoporosis Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis.	1.97	1	0

1-hydroxyprevitamin d3

Description

Cross-References

Synonyms (8)

Research

Studies (6)

Market Indicators

Research Demand Index: 12.28

Study Types